Subsequently, a resulting increased DFS was observed, with higher rates in the luminal A (p < 0.0001), luminal B/HER2-negative (p = 0.01), and luminal B/HER2-positive breast cancer groups (p < 0.0001; Fig. 6). This evidence concerns the gene ERBB2 and breast cancer.